Skip to main content
VREOF
OTC Life Sciences

Vireo 10-Q: Q3 Revenue $253.7M, Net Loss $24.0M, Debt Nearly Doubles to $293M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Neutral
Importance info
7
Price
$6.76
Mkt Cap
$351.897M
52W Low
$6.4
52W High
$21.762
52W Position info
5.6% above low
Off High info
69% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

VREOF is trading near its 52-week low of $6.4 (5.6% above the low).

Summary

Vireo's Q3 10-Q confirms $253.7M revenue but a $24.0M net loss driven by $34.8M of current tax expense, with long-term debt up to $293.0M and cash down to $88.8M. It also details the post-quarter $60.0M Needham refinancing and the November 9 Fluent acquisition close.


Key Events · Earnings and Guidance · VREOF

  • Q3 Revenue $253.7M, Net Loss $24.0M

    Revenue rose 177% to $253.7M from $91.7M, but net loss was $24.0M as current income tax expense of $34.8M exceeded $4.0M of pre-tax income.

  • Debt Nearly Doubles, Cash Falls

    Total long-term debt reached $293.0M at September 30, 2026 versus $143.9M at December 31, 2025, while cash dropped to $88.8M from $102.2M.

  • Non-Cannabis Segment at 13% Margin

    Hawthorne and Bridgewell contributed $55.6M of Q3 revenue but only $7.4M of gross profit, a 13% margin versus 51% for cannabis.

  • Needham Loan Refinances 15% Seller Note

    On October 2, 2026 the company closed a $60.0M Needham Bank term loan at 8.50% fixed, replacing the $49.0M IIP seller note and adding $11.0M of principal.


Analysis · VREOF · Life Sciences

The headline numbers were already out in the November 10 8-K, but the full 10-Q shows what sits underneath them. Revenue of $253.7M in the quarter carried a $24.0M net loss because current income tax expense of $34.8M swamped $4.0M of pre-tax income. The balance sheet has also changed shape fast: long-term debt rose to $293.0M from $143.9M at year-end while cash fell to $88.8M from $102.2M. The new Non-Cannabis segment (Hawthorne plus Bridgewell) added $55.6M of revenue but only a 13% gross margin, well below the 51% cannabis margin, so the mix shift matters for future profitability. Two post-quarter events also landed: a $60.0M Needham Bank loan at 8.50% that refinanced the 15% IFS seller note, and the Fluent acquisition closing November 9 with 6,148,780 shares issued, 3,884,062 of them to CEO-affiliated Chicago Atlantic.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VREOF was trading at $6.76 on OTC in the Life Sciences sector, with a market capitalization of approximately $351.9M. The 52-week trading range was $6.40 to $21.76. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VREOF - Latest Insights

VREOF
Nov 10, 2026, 4:05 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $6.68
Real-time Price: $6.76 info
Change: +$0.080 (+1%) info
Market Cap: $351.897M info
VREOF
Nov 10, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.78
Real-time Price: $6.76 info
Change: -$0.020 (-0.29%) info
Market Cap: $351.897M info
VREOF
Oct 30, 2026, 4:15 PM EDT
Filing Type: S-4/A
Importance Score:
7
Price at Filing: $7.35
Real-time Price: $6.76 info
Change: -$0.590 (-8%) info
Market Cap: $351.897M info
VREOF
Oct 09, 2026, 4:34 PM EDT
Filing Type: S-4
Importance Score:
8
Price at Filing: $9.38
Real-time Price: $6.76 info
Change: -$2.62 (-28%) info
Market Cap: $351.897M info
VREOF
Oct 08, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.21
Real-time Price: $6.76 info
Change: -$2.45 (-27%) info
Market Cap: $351.897M info